137 related articles for article (PubMed ID: 34554822)
21. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
22. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
23. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
24. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Yagata H; Kajiura Y; Yamauchi H
Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
[TBL] [Abstract][Full Text] [Related]
25. Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy?
Chaudhary LN; Wilkinson KH; Kong A
Surg Oncol Clin N Am; 2018 Jan; 27(1):141-153. PubMed ID: 29132557
[TBL] [Abstract][Full Text] [Related]
26. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer.
Nakatsukasa K; Koyama H; Oouchi Y; Imanishi S; Mizuta N; Sakaguchi K; Fujita Y; Fujiwara I; Kotani T; Matsuda T; Fukuda K; Morita M; Kawakami S; Kadotani Y; Konishi E; Yanagisawa A; Taguchi T
Breast Cancer; 2017 Jan; 24(1):63-68. PubMed ID: 26754092
[TBL] [Abstract][Full Text] [Related]
28. De-escalating and escalating systemic therapy in triple negative breast cancer.
Carey LA
Breast; 2017 Aug; 34 Suppl 1():S112-S115. PubMed ID: 28690105
[TBL] [Abstract][Full Text] [Related]
29. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
30. Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer.
Okines A; Turner N
Ann Oncol; 2022 Jun; 33(6):657-658. PubMed ID: 35301095
[No Abstract] [Full Text] [Related]
31. Breast Cancer Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy by Receptor Subtype: A Scoping Review.
Stankowski-Drengler TJ; Livingston-Rosanoff D; Schumacher JR; Hanlon BM; Hitchcock ME; Neuman HB
J Surg Res; 2020 Oct; 254():83-90. PubMed ID: 32422430
[TBL] [Abstract][Full Text] [Related]
32. Features from Computerized Texture Analysis of Breast Cancers at Pretreatment MR Imaging Are Associated with Response to Neoadjuvant Chemotherapy.
Chamming's F; Ueno Y; Ferré R; Kao E; Jannot AS; Chong J; Omeroglu A; Mesurolle B; Reinhold C; Gallix B
Radiology; 2018 Feb; 286(2):412-420. PubMed ID: 28980886
[TBL] [Abstract][Full Text] [Related]
33. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
Pandy JGP; Balolong-Garcia JC; Cruz-Ordinario MVB; Que FVF
BMC Cancer; 2019 Nov; 19(1):1065. PubMed ID: 31703646
[TBL] [Abstract][Full Text] [Related]
34. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response.
Fisher CS; Ma CX; Gillanders WE; Aft RL; Eberlein TJ; Gao F; Margenthaler JA
Ann Surg Oncol; 2012 Jan; 19(1):253-8. PubMed ID: 21725686
[TBL] [Abstract][Full Text] [Related]
36. Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer.
Davis AA; Gradishar WJ
Oncology (Williston Park); 2020 May; 34(5):176-182. PubMed ID: 32644178
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis.
Bianco N; Palazzo A; Pagan E; Bagnardi V; Milano M; De Maio AP; Colleoni M
Breast; 2021 Oct; 59():351-357. PubMed ID: 34407499
[TBL] [Abstract][Full Text] [Related]
39. Extent of Breast Surgery After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer.
Benson JR; Dumitru D
JAMA Surg; 2020 Aug; 155(8):784-785. PubMed ID: 32401292
[No Abstract] [Full Text] [Related]
40. Extent of Breast Surgery After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer.
Ponzone R; Montemurro F
JAMA Surg; 2020 Aug; 155(8):785-786. PubMed ID: 32401290
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]